GlassScriptPhysician profile
Maggie W Chen
NPI 1649470683
$6,485.65
in general payments reported to CMS, 2019-2025
32 companies · $878 in 2025
The $878 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,551 · 2020: $761 · 2021: $709 · 2022: $767 · 2023: $760 · 2024: $1,061 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,668 · Education: $30.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,667.98 |
| Education | $30.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $909.38 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $740.92 | 2019-2024 | Velphoro |
| Amgen INC. | $612.41 | 2019-2025 | Krystexxa, Parsabiv, Tavneos |
| Ardelyx, INC. | $550.75 | 2023-2025 | Ibsrela |
| Vifor Pharma, INC. | $508.26 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $458.54 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $436.98 | 2019-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $339.84 | 2019-2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $290.44 | 2022-2025 | Tarpeyo |
| Abbvie INC. | $193.13 | 2019-2021 | |
| Akebia Therapeutics INC | $172.85 | 2019-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.25 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $148.03 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.45 | 2021-2025 | |
| Radius Health, INC. | $125.00 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $118.85 | 2019 | |
| Sanofi-Aventis U.S. LLC | $81.53 | 2019-2020 | |
| Genzyme Corporation | $57.71 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $56.41 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $55.24 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $53.73 | 2024-2025 | |
| Novo Nordisk INC | $46.46 | 2019-2022 | |
| Glaxosmithkline, LLC. | $38.65 | 2023-2024 | Jesduvroq, Benlysta |
| Lilly USA, LLC | $29.65 | 2024 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $27.24 | 2024 | Arcalyst |
| Strata Skin Sciences, INC. | $25.42 | 2024 | Xtrac |
| Kyowa Kirin, INC. | $23.77 | 2025 | |
| Avanir Pharmaceuticals, INC. | $19.71 | 2020 | |
| Vivus LLC | $17.90 | 2022 | |
| Travere Therapeutics, INC. | $16.00 | 2023-2024 | |
| Qiagen, LLC | $13.47 | 2020 | |
| Allergan, INC. | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maggie Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.